- 26. (New) The medicament according to claim 1 wherein the therapeutically effective amount of at least one nicotine based substance is administered intranasally.
- 27. (New) The medicament according to claim 1 wherein the therapeutically effective amount of at least one nicotine based substance is administered intravaginally.
- 28. (New) The medicament according to claim 1 wherein the at least one nicotine based substance includes substantially pure nicotine.
- 29. (New) The medicament according to claim 1 wherein the at least one nicotine based substance includes nicotine derivatives, intermediate metabolite of nicotine, or degradation products of nicotine.
- 30. (New) The medicament according to claim 1 wherein the at least one nicotine based substance is absorbed by a binding agent.
- 31. (New) The medicament according to claim 1 wherein the therapeutically effective amount of at least one nicotine based substance is administered to a mammal having a congenital bilateral bronchial anomaly.

<u>REMARKS</u>

The above amendments are being made to place the application in better form for prosecution, to include the amended claims of the International Application, and to remove multiple dependencies from its claims.

Should the Examiner have any questions regarding the present application, Applicant respectfully requests that the Examiner contact Applicants' representative at the phone number listed below. While Applicant believes no

fees are due with the filing of this amendment, please charge any deficiencies in fees associated with this filing to our Deposit Account No. 13-0235.

Respectfully submitted,

Richard R. Michaud Registration No. 40,088

Attorney for Applicant

McCormick, Paulding & Huber LLP CityPlace II 185 Asylum Street Hartford, Connecticut 06103-3402 (860) 549-5290